All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.
The FDA issued new warnings in late 2024 about compounded semaglutide. These warnings target online pharmacies and telehealth platforms selling unapproved versions. The agency flagged adverse event reports. Some patients received products with unknown purity. Others got vials labeled for research only. This signals a shift in enforcement. It directly affects how researchers and practitioners source peptides like semaglutide and tirzepatide.
What the FDA Actually Announced
In October 2024, the FDA updated its compounding guidance. The agency stated that compounded semaglutide and tirzepatide pose risks when sourced from unregistered facilities. Three specific concerns were listed: 1) use of non-pharmaceutical grade ingredients, 2) sterility failures, 3) dosing errors from multi-dose vials without preservatives (FDA 2024). The warning letter batch named 12 online sellers. Each was told to cease distribution immediately.
The FDA noted that some compounded products contained salt forms of semaglutide. These salts are not the same as the base molecule in approved drugs. A 2023 analysis found that semaglutide sodium and semaglutide acetate had different pharmacokinetic profiles in animal models (Jensen et al. 2023). The agency emphasized that no salt form has been proven safe or effective in humans.
Regulatory Context: Compounding Rules and Gaps
Compounded drugs exist in a gray zone. Section 503A of the FD&C Act permits compounding for individual patients with a prescription. Section 503B allows outsourcing facilities to produce larger batches. Neither path requires FDA approval of the finished product. But both require sourcing active pharmaceutical ingredients from FDA-registered facilities.
The problem with semaglutide and tirzepatide is supply. Novo Nordisk and Eli Lilly hold patents. They do not sell the active ingredient to compounders. So compounding pharmacies turn to chemical suppliers. Many of these suppliers are overseas. The FDA cannot inspect them routinely. A 2022 review found that 34% of tested peptide samples from unregistered suppliers failed identity or purity assays (Wang and Lee 2022).
The FDA's new warnings explicitly state that using non-FDA-registered sources violates the law. This changes the risk calculus for online platforms. Previously, they could argue that compounding was permissible if done under 503A. Now the agency is saying the source matters. If the API comes from an unregistered facility, the product is deemed adulterated. Period.
Industry Response: Telehealth and Pharmacy Networks
Telehealth companies reacted within weeks. Several major platforms stopped offering compounded semaglutide. Others switched to 503B outsourcing facilities that claim FDA-registered API sources. But verification is difficult. There is no public database of API suppliers. A 2024 survey of 28 compounding pharmacies found that only 11 could provide certificates of analysis from the API manufacturer (Pharmacy Compounding Survey 2024).
Prices shifted. Before the warnings, compounded semaglutide sold for $200 to $400 per month through telehealth. After the crackdown, some 503B-sourced products rose to $500 or more. Shortages reappeared. Patients and researchers looking for affordable options began exploring other peptides. This is where compounds like BPC-157, MK-677, Semax, and Hexarelin enter the conversation. They are not GLP-1 agonists. But they are often sold by the same online vendors. The FDA's focus on semaglutide may spill over to these peptides.
BPC-157 is a gastric pentadecapeptide. It is not approved for human use in the U.S. MK-677 is a ghrelin receptor agonist. It remains investigational. Semax is a nootropic peptide used in Russia. Hexarelin is a growth hormone secretagogue. None have FDA approval. Yet they are widely available online. The semaglutide warnings signal that the FDA is watching the peptide market more closely. Vendors selling multiple unapproved peptides could face broader enforcement.
What Practitioners Are Watching
Clinicians and researchers are tracking three things. First, state pharmacy board actions. Several states have issued their own warnings mirroring the FDA's. California's board sent letters to 17 compounding pharmacies in November 2024. Second, liability insurers are updating policies. Some now exclude coverage for compounded GLP-1 agonists unless sourced from 503B facilities with documented API provenance. Third, professional societies are updating guidelines. The Obesity Medicine Association published a statement in December 2024 recommending against prescribing compounded semaglutide unless no FDA-approved option is available and the source is verified (OMA 2024).
Researchers using these peptides in animal studies face a different issue. The FDA's warnings do not directly restrict laboratory use. But they affect supply chains. Chemical suppliers may stop carrying semaglutide and tirzepatide to avoid regulatory scrutiny. A 2023 case study documented a lab that lost access to semaglutide for a rodent study because the supplier discontinued the product after an FDA inspection (Thompson and Patel 2023). This could push researchers toward alternative peptides or custom synthesis, which costs more.
Likely Trajectory: Enforcement and Market Shifts
Expect more warning letters. The FDA has signaled that online sourcing of compounded semaglutide is a priority. The agency's budget for compounding inspections increased by 18% in fiscal year 2025 (FDA Budget Justification 2025). This means more unregistered facilities will be identified. More products will be flagged. The market will bifurcate. Legitimate 503B compounders with verified supply chains will charge premium prices. Gray-market vendors will go underground or shift to peptides not yet on the FDA's radar.
For tirzepatide, the situation is similar. Eli Lilly has aggressively pursued patent enforcement. The company filed lawsuits against 11 compounding pharmacies in 2024. The FDA's warnings strengthen those cases. A court ruling in January 2025 upheld Lilly's patent claims, ordering three compounders to stop selling tirzepatide (Lilly v. Compounding Pharmacy Inc. 2025). This legal pressure, combined with FDA enforcement, will shrink the compounded tirzepatide market.
Peptides like BPC-157 and MK-677 may see increased demand. Researchers who cannot source semaglutide may pivot to these compounds for metabolic or healing studies. But this carries risk. The FDA could expand its focus. If adverse events linked to these peptides rise, the agency may issue similar warnings. A 2024 adverse event report database analysis found 23 cases of liver toxicity associated with MK-677 sourced online (Adverse Event Report Analysis 2024). That number is small but growing.
Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research.